Flerie AB:s wholly-owned subsidiary, Flerie Invest AB, Reg No. 556856-6615 (“Flerie”) has today acquired 666,570 shares in Nanologica AB (publ), Reg. No. 556664-5023 (“Nanologica”). Flerie’s total holding in Nanologica following the acquisition amounts to 38,222,779 shares, comprising approximately 43.26 per cent of the total amount of shares and votes in the company.

According to the Swedish Securities Council's statement AMN 2024:62, Flerie was granted an exemption from the obligation to make a mandatory bid that could arise as a result of Flerie (i) subscribing its share in the rights issue of units that Nanologica carried out in 2024, and (ii) utilised the warrants acquired through the rights issue for share subscription. According to the exception, an obligation to make a mandatory bid arises if Flerie subsequently acquires additional shares and thereby increases its voting rights in Nanologica.

Through today's acquisition of additional shares in Nanologica, an obligation to make a mandatory bid arises. Flerie intends to revert with information regarding a possible public takeover bid regarding the remaining shares in Nanologica within four weeks.

For further information, please contact:

Cecilia Stureborg von Schéele, CFO of Flerie

E-mail: ir@flerie.com

This information was submitted for publication on 25 April 2025 at 19.15 CEST.

About Flerie

Flerie is an active long-term life science investor, with a broad and diversified portfolio of innovative companies based on pioneering science. We invest in product development and commercial growth opportunities globally alongside other leading investors, focusing predominantly on private companies that are otherwise difficult to access. Flerie’s active ownership model, broad network and resources support and accelerate the development of the portfolio projects, creating value for shareholders. Flerie AB’s ordinary share is listed on Nasdaq Stockholm with the ticker FLERIE. For further information please visit www.flerie.com.